Clinical translation of immunoliposomes for cancer therapy: recent perspectives

References

• Jain A, Jain SK. Advances in tumor targeted liposomes. Curr Mol Med. 2018;18:44–57.
   PubMed Web of Science ®Google Scholar
• Eloy JO, de Souza MC, Petrilli R, et al. Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery. Colloids Surf B Biointerfaces. 2014;123:345–363.
   PubMed Web of Science ®Google Scholar
• Gharib R, Greige-Gerges H, Fourmentin S, et al. Liposomes incorporating cyclodextrin-drug inclusion complexes: current state of knowledge. Carbohyd Polym. 2015;129:175–186.
   PubMed Web of Science ®Google Scholar
• Shim G, Kim MG, Park JY, et al. Application of cationic liposomes for delivery of nucleic acids. Asian J Pharm Sci. 2013;8:72–80.
   Google Scholar
• Maeki M, Kimura N, Sato Y, et al. Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems. Adv Drug Deliver Rev. 2018;128:84–100.
   PubMed Web of Science ®Google Scholar
• Fathi S, Oyelere AK. Liposomal drug delivery systems for targeted cancer therapy: is active targeting the best choice? J Med Chem. 2016;8:2091–2112.
   Google Scholar
• Barenholz Y. Doxil(R)–the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117–134.
   PubMed Web of Science ®Google Scholar
• Roveri M, Pfohl A, Jaaks P, et al. Prolonged circulation and increased tumor accumulation of liposomal vincristine in a mouse model of rhabdomyosarcoma. Nanomedicine (UK). 2017;12:1135–1151.
   PubMed Web of Science ®Google Scholar
• Wu H, Infante JR, Keedy VL, et al. Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors. Int J Nanomedicine. 2015;10:1201–1209.
   PubMed Web of Science ®Google Scholar
• Zwaan CM, Dworzak M, Klingebiel T, et al. Safety and pharmacokinetics of clofarabine in combination with high-dose cytarabine and liposomal daunorubicin in pediatric AML: results of a phase 1 combination study by the ITCC consortium. Blood. 2013;122:2693.
   Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271–284.
   PubMed Web of Science ®Google Scholar
• Feldman EJ, Lancet J, Kolitz JE, et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011;29:979–985.
   PubMed Web of Science ®Google Scholar
• Cho H, Stuart JM, Magid R, et al. Theranostic immunoliposomes for osteoarthritis. Nanomedicine. 2014;10:619–627.
   PubMed Web of Science ®Google Scholar
• Cheng X, Lee RJ. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev. 2016;99:129–137.
   PubMed Web of Science ®Google Scholar
• Kraft JC, Freeling JP, Wang Z, et al. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci. 2014;103:29–52.
   PubMed Web of Science ®Google Scholar
• Wan C, Allen TM, Cullis PR. Lipid nanoparticle delivery systems for siRNA-based therapeutics. Drug Deliv Transl Res. 2014;4:74–83.
   PubMed Web of Science ®Google Scholar
• Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. Mol Ther. 2017;25:1467–1475.
   PubMed Web of Science ®Google Scholar
• Yu B, Hsu SH, Zhou CG, et al. Lipid nanoparticles for hepatic delivery of small interfering RNA. Biomaterials. 2012;33:5924–5934.
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11–21.
   PubMed Web of Science ®Google Scholar
• Mo LX, Song JG, Lee H, et al. PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure. Nanomedicine (UK). 2018;14:557–567.
   PubMed Web of Science ®Google Scholar
• Eloy JO, Petrilli R, Trevizan LNF, et al. Immunoliposomes: A review on functionalization strategies and targets for drug delivery. Colloids Surf B Biointerfaces. 2017;159:454–467.
   PubMed Web of Science ®Google Scholar
• Merino M, Zalba S, Garrido MJ. Immunoliposomes in clinical oncology: state of the art and future perspectives. J Control Release. 2018;275:162–176.
   PubMed Web of Science ®Google Scholar
• Manjappa AS, Chaudhari KR, Venkataraju MP, et al. Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release. 2011;150:2–22.
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Immunoliposomes for cancer therapy. Curr Opin Mol Ther. 2006;8:39–45.
   PubMed Web of Science ®Google Scholar
• Beck A, Goetsch L, Dumontet C, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16:315–337.
   PubMed Web of Science ®Google Scholar
• Wolf-Dieter J, Nathan C, Christoph M. Drug conjugates such as antibody drug conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. Int J Mol Sci. 2012;13:16020–16045.
   PubMed Web of Science ®Google Scholar
• Tsuchikama K, An ZQ. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9:33–46.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65:36–48.
   PubMed Web of Science ®Google Scholar
• He CS, Li JS, Cai P, et al. Two-step targeted hybrid nanoconstructs increase brain penetration and efficacy of the therapeutic antibody trastuzumab against brain metastasis of HER2-positive breast cancer. Adv Funct Mater. 2018;28:1705668.
   Web of Science ®Google Scholar
• Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol. 2002;29:47–50.
   PubMed Web of Science ®Google Scholar
• Sims JD, Taguaim M, Hanson C, et al. A human epidermal growth factor receptor 3 (HER3)-binding nanoparticle targets and kills Herceptin®-resistant human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Cancer Res. 2013;73: P5-08-08.
   PubMed Web of Science ®Google Scholar
• Soda H, Maeda H, Hasegawa J, et al. Multicenter phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: the FLEET study. BMC Cancer. 2015;15:695.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Gotoh M, Muro K, et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol. 2004;15:517–525.
   PubMed Web of Science ®Google Scholar
• Weng KC, Noble CO, Papahadjopoulos-Sternberg B, et al. Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett. 2008;8:2851–2857.
   PubMed Web of Science ®Google Scholar
• Koren E, Apte A, Jani A, et al. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J Control Release. 2012;160:264–273.
   PubMed Web of Science ®Google Scholar
• Mortensen JH, Jeppesen M, Pilgaard L, et al. Targeted antiepidermal growth factor receptor (cetuximab) immunoliposomes enhance cellular uptake in vitro and exhibit increased accumulation in an intracranial model of glioblastoma multiforme. J Drug Deliv. 2013;2013:209205.
   PubMedGoogle Scholar
• Garfftavernier ML, Herbi L, Romeuf CD, et al. Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion. Leukemia. 2014;28:230–233.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Hollyman D, Weiss M, et al. A phase I trial for the treatment of purine analog-refractory chronic lymphocytic leukemia using autologous T cells genetically targeted to the B cell specific antigen CD19. J Clin Oncol. 2008;26:753–754.
   PubMed Web of Science ®Google Scholar
• Mazor Y, Sachsenmeier KF, Yang C, et al. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. Sci Rep. 2017;7:40098.
   PubMed Web of Science ®Google Scholar
• Ishihara T, Nakajima N, Kadoya T. Evaluation of new affinity chromatography resins for polyclonal, oligoclonal and monoclonal antibody pharmaceuticals. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:2141–2144.
   PubMed Web of Science ®Google Scholar
• Hultqvist G, Syvänen S, Fang XT, et al. Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor. Theranostics. 2017;7:308–318.
   PubMed Web of Science ®Google Scholar
• Sung AP, Tang JJ, Guglielmo MJ, et al. An improved method to quantify human NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) per IgG FcR-positive NK cell without purification of NK cells. J Immunol Methods. 2017;452:63–72.
   PubMed Web of Science ®Google Scholar
• Mirick GR, Bradt BM, Denardo SJ, et al. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q J Nucl Med Mol Imaging. 2004;48:251–257.
   PubMed Web of Science ®Google Scholar
• Schuster L, Seifert O, Vollmer S, et al. Immunoliposomes for targeted delivery of an antifibrotic drug. Mol Pharm. 2015;12:3146–3157.
   PubMed Web of Science ®Google Scholar
• Ma H, O’Kennedy R. Recombinant antibody fragment production. Methods. 2017;116:23–33.
   PubMed Web of Science ®Google Scholar
• Cheng WW, Allen TM. The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment. Expert Opin Drug Del. 2010;7:461–478.
   PubMed Web of Science ®Google Scholar
• Cheng M, Santich BH, Xu H, et al. Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors. Oncoimmunology. 2016;5:e1168557.
   PubMed Web of Science ®Google Scholar
• Kim JS, Shin DH, Kim JS. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells. J Control Release. 2017;269:245–257.
   PubMed Web of Science ®Google Scholar
• Zhou G, Wilson G, Hebbard L, et al. Aptamers: A promising chemical antibody for cancer therapy. Oncotarget. 2016;7:13446–13463.
   PubMedGoogle Scholar
• Chandan R, Banerjee R. Pro-apoptotic liposomes-nanobubble conjugate synergistic with paclitaxel: a platform for ultrasound responsive image-guided drug delivery. Sci Rep. 2018;8.
   PubMed Web of Science ®Google Scholar
• Wicki A, Ritschard R, Loesch U, et al. Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial. Int J Pharm. 2015;484:8–15.
   PubMed Web of Science ®Google Scholar
• Smith JA, Costales AB, Jaffari M, et al. Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment. J Oncol Pharm Pract. 2016;22:599.
   PubMed Web of Science ®Google Scholar
• Dos SN, Allen C, Doppen AM, et al. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta. 2007;1768:1367–1377.
   PubMed Web of Science ®Google Scholar
• Balguri SP, Adelli GR, Janga KY, et al. Ocular disposition of ciprofloxacin from topical, PEGylated nanostructured lipid carriers: effect of molecular weight and density of poly (ethylene) glycol. Int J Pharm. 2017;529:32–43.
   PubMed Web of Science ®Google Scholar
• Lee H, Larson RG. Adsorption of plasma proteins onto PEGylated lipid bilayers: the effect of PEG size and grafting density. Biomacromolecules. 2016;17:1757–1765.
   PubMed Web of Science ®Google Scholar
• Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13:655–672.
   PubMed Web of Science ®Google Scholar
• Qhattal HSS, Hye T, Alali A, et al. Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes. Acs Nano. 2014;8:5423–5440.
   PubMed Web of Science ®Google Scholar
• Pozzi D, Colapicchioni V, Caracciolo G, et al. Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells. Nanoscale. 2014;6:2782–2792.
   PubMed Web of Science ®Google Scholar
• Hou XP, Zhang YF, Xie SS, et al. Study on third-type immunoliposomes loaded drugs and the targeting in vitro and in vivo. Acta Pharm Sin B. 2001;36:539–542.
   Google Scholar
• Jayanna PK, Torchilin VP, Petrenko VA. Liposomes targeted by fusion phage proteins. Nanomedicine (UK). 2009;5:83.
   PubMed Web of Science ®Google Scholar
• Needham D, Kim DH. PEG-covered lipid surfaces: bilayers and monolayers. Colloids Surf B Biointerfaces. 2000;18:183.
   PubMed Web of Science ®Google Scholar
• Béduneau A, Saulnier P, Hindré F, et al. Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab’ fragments. Biomaterials. 2007;28:4978–4990.
   PubMed Web of Science ®Google Scholar
• Simard P, Leroux JC. pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells. Int J Pharm. 2009;381:86–96.
   PubMed Web of Science ®Google Scholar
• Alric C, Aubrey N, Allard-Vannier É, et al. Covalent conjugation of cysteine-engineered scFv to PEGylated magnetic nanoprobes for immunotargeting of breast cancer cells. RSC Adv. 2016;6:37099–37109.
   Web of Science ®Google Scholar
• Miller K, Cortes J, Hurvitz SA, et al. HERMIONE: a randomized phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer. 2016;16:352.
   PubMed Web of Science ®Google Scholar
• Boland CR. Taking the starch out of hereditary colorectal cancer. Lancet Oncol. 2012;13:1179–1180.
   PubMed Web of Science ®Google Scholar
• Yang YF, Xie XY, Yang Y. A review on the influences of size and surface charge of liposome on its targeted drug delivery in vivo. Acta Pharm Sin B. 2013;48:1644–1650.
   Google Scholar
• Lu XF, Zhou Y, Zhang J, et al. Pharmacokinetics and tissue distribution of larotaxel in rats: comparison of larotaxel solution with larotaxel-loaded folate receptor-targeting amphiphilic copolymer-modified liposomes. Xenobiotica. 2017;47:416–422.
   PubMed Web of Science ®Google Scholar
• Tang Y, Soroush F, Sheffield JB, et al. A biomimetic microfluidic tumor microenvironment platform mimicking the EPR effect for rapid screening of drug delivery systems. Sci Rep. 2017;9359.
   PubMed Web of Science ®Google Scholar
• Iyer AK, Khaled G, Fang J, et al. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006;11:812–818.
   PubMed Web of Science ®Google Scholar
• Heldin CH, Rubin K, Pietras K, et al. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer. 2004;4:806.
   PubMed Web of Science ®Google Scholar
• Belfiore L, Saunders DN, Ranson M, et al. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: challenges and opportunities. J Control Release. 2018;277:1–13.
   PubMed Web of Science ®Google Scholar
• Chen YQ, Ma GL, Su CY, et al. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines. Anticancer Drugs. 2018 Aug 2. doi: 10.1097/CAD.0000000000000667. [Epub ahead of print].
   Google Scholar
• Shallal H, Minn I, Banerjee SR, et al. Heterobivalent agents targeting PSMA and integrin-αvβ3. Bioconjug Chem. 2014;25:393–405.
   PubMed Web of Science ®Google Scholar
• Howard CB, Fletcher N, Houston ZH, et al. Overcoming instability of antibody-nanomaterial conjugates: next generation targeted nanomedicines using bispecific antibodies. Adv Healthc Mater. 2016;5:2055–2068.
   PubMed Web of Science ®Google Scholar
• Morgan SB, Holzer B, Hemmink JD, et al. Therapeutic administration of broadly neutralizing FI6 antibody reveals lack of interaction between human IgG1 and pig Fc receptors. Front Immunol. 2018;9:865.
   PubMed Web of Science ®Google Scholar
• Wagner A, Vorauer-Uhl K. Liposome technology for industrial purposes. J Drug Deliv. 2011;2011:591325.
   PubMedGoogle Scholar
• Van SD, Demello A. Microfluidic methods for forming liposomes. Lab Chip. 2013;13:752–767.
   PubMed Web of Science ®Google Scholar
• Ran R, Wang H, Liu Y, et al. Microfluidic self-assembly of a combinatorial library of single- and dual-ligand liposomes for in vitro and in vivo tumor targeting. Eur J Pharm Biopharm. 2018;130:1–10.
   PubMed Web of Science ®Google Scholar
• Mack K, Rüger R, Fellermeier S, et al. Dual targeting of tumor cells with bispecific single-chain Fv-immunoliposomes. Antibodies. 2012;1:199–214.
   Google Scholar
• Viswanathan S, Rani C, Deleruematos C. Ultrasensitive detection of ovarian cancer marker using immunoliposomes and gold nanoelectrodes. Analytica Chimica Acta. 2012;726:79–84.
   PubMed Web of Science ®Google Scholar
• Geest TVD, Laverman P, Metselaar JM, et al. Radionuclide imaging of liposomal drug delivery. Expert Opin Drug Deliv. 2016;13:1231–1242.
   PubMed Web of Science ®Google Scholar
• Zhuo HQ, Zheng BS, Liu JM, et al. Efficient targeted tumor imaging and secreted endostatin gene delivery by anti-CD105 immunoliposomes. J Exp Clin Cancer Res. 2018;37:42.
   PubMed Web of Science ®Google Scholar
• Tansi FL, Ruger R, Bohm C, et al. Potential of activatable FAP-targeting immunoliposomes in intraoperative imaging of spontaneous metastases. Biomaterials-UK. 2016;88:70–82.
   PubMed Web of Science ®Google Scholar
• Yuba E. Liposome-based immunity-inducing systems for cancer immunotherapy. Mol Immunol. 2017;98:8–12.
   PubMed Web of Science ®Google Scholar